Repurposing mebendazole against triple-negative breast cancer leptomeningeal disease
Adrian Rodrigues(Unidade Hospitalar de Bragança), Melanie Hayden Gephart(Stanford Medicine), David E. Solow-Cordero(High Throughput Biology (United States)), Tyler J. Quill(Stanford University), L. А. Alexandrova, Ashley K. Koegel(Bristol-Myers Squibb (United States)), Elizabeth Alli(Wake Forest University), Kerriann M. Casey(Stanford University), Yuelong Wang(Huaqiao University), Sophia B. Chernikova(Stanford Medicine), Thy Trinh(Stanford Medicine), James M. Ford(Palo Alto University), Brian J. Feldman(University of California, San Francisco), Abhishek Aggarwal(Amazon (Germany))
Cited by 0
Related Papers
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
|Clinical Cancer Research|2016|1.2k
The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution
|Cell|2020|614
Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline <i>CDH1</i> mutation carriers
|Journal of Medical Genetics|2015|567
Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines
|PLoS ONE|2012|528
Hereditary diffuse gastric cancer: updated clinical practice guidelines
|The Lancet Oncology|2020|493